Cramer Is ‘Astonished’ That Chewy Is ‘Doing This Poorly — So Many Of Us Use It’

On CNBC’s "Mad Money Lightning Round," Jim Cramer said yes to The St. Joe Company (NYSE: JOE). "I’ve liked St. Joe forever," he added.

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said yes to The St. Joe Company (NYSE:JOE). “I’ve liked St. Joe forever,” he added.

When asked about Advance Auto Parts, Inc. (NYSE:AAP), he said, “I like to buy best of breed, the best of breed is AutoZone, Inc. (NYSE:AZO).”

Cramer also said he is astonished that Chewy, Inc. (NYSE:CHWY) is “doing this poorly, because so many of us use it.”

Don’t forget to check out our premarket coverage here

“There is now beginning to be a credibility gap between what the company said about the problems with the engines and what’s actually happening,” Cramer said about RTX Corporation (NYSE:RTX). “No bottom yet, not yet, still sells at 15 times earnings, got to go lower.”

The “Mad Money” host said he prefers Chipotle Mexican Grill, Inc. (NYSE:CMG) over CAVA Group, Inc. (NYSE:CAVA).

When asked about Illumina, Inc. (NASDAQ:ILMN), he said, “I don’t think it’s a great company, I think it’s a very good technology business that is not a great company. Danaher Corporation (NYSE:DHR) is the one to buy.”

Price Action: Shares of Danaher gained 1.7% to close at $252.45, while Illumina gained 0.2% to $150.77 on Wednesday. CAVA shares fell 1% to settle at $35.64, while Chipotle closed at $1,933.04 on Wednesday. RTX shares settled at $75.56, while Chewy fell 1.8% to close at $21.51 on Wednesday. AutoZone shares gained 0.2% to $2,531.04, while Advance Auto Parts gained 0.8% to $57.93. St. Joe Company shares declined 2.9% to close at $57.60 on Wednesday.

Now Read This: Top 5 Tech And Telecom Stocks You May Want To Dump In Q3

Total
0
Shares
Related Posts
Read More

Immuron Announced US DoD Naval Medical Research Center Received feedback on IND Application for New Campylobacter ETEC Therapeutic; Said IND Does Not Contain Sufficient Information

:Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) applica

IMRN